Sleep medicine: pediatric polysomnography revisited
CURRENT OPINION IN PEDIATRICS
2015; 27 (3): 325-328
Pulmonary nocardiosis in an immunocompetent patient with cystic fibrosis.
Case reports in pulmonology
2015; 2015: 984171-?
Sleep medicine is an increasingly well subscribed component of pediatric medicine. While knowledge has increased significantly in the past five decades, whether the most widely used tool to assess sleep-disordered breathing possesses demonstrable clinical utility remains unknown. The absence of certainty surrounding the impact of polysomnography (PSG) testing on clinical outcomes, superimposed on the cost and inconvenience of PSG testing, prompts a call to reassess the current normative stance toward PSG testing.The present study argues for the use of the following: endpoints that have known clinical significance; readily available data provided by parents; and data derived from a randomized, placebo-controlled trial to determine the merits of PSG testing in the context of obstructive sleep apnea.By rationalizing the use PSG testing, cost, inconvenience, and parental anxiety can be decreased without compromising care.
View details for DOI 10.1097/MOP.0000000000000219
View details for Web of Science ID 000354214800010
Nocardia spp. are bacteria of low virulence that cause infection classically in immunocompromised hosts with the lungs as the primary site of infection in the majority of cases. Patients with cystic fibrosis have pulmonary disease characterized by frequent and progressive bacterial infections. Reports of Nocardia spp. isolation in CF are rare in the literature and may represent colonization or active infection, the significance and optimal treatment of which are unknown. We report the second case to date of Nocardia transvalensis pulmonary infection in an immunocompetent patient with CF and the first in a child under the age of eighteen.
View details for DOI 10.1155/2015/984171
View details for PubMedID 25960909